STOCK TITAN
  1. Home
  2. News
  3. STOK

Stoke Therapeutics Inc - STOK STOCK NEWS

Welcome to our dedicated news page for Stoke Therapeutics (Ticker: STOK), a resource for investors and traders seeking the latest updates and insights on Stoke Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Stoke Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Stoke Therapeutics's position in the market.

News
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
Rhea-AI Summary
Stoke Therapeutics appoints Jason Hoitt as Chief Commercial Officer, bringing over 20 years of experience in commercial strategies for rare diseases. Mr. Hoitt will lead the global commercial strategy for STK-001, a potential disease-modifying medicine for Dravet syndrome. His appointment aims to drive growth and prepare for the registrational study of STK-001.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Stoke Therapeutics, Inc. (STOK) to present at the 23rd Annual Needham Virtual Healthcare Conference. The presentation will focus on upregulating protein expression with RNA-based medicines. Live webcast available on the company's website. Replay accessible for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
conferences
-
News
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
Rhea-AI Summary
Stoke Therapeutics, Inc. announces the pricing of an upsized public offering, aiming to raise $125 million through the sale of common stock and pre-funded warrants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.73%
Tags
offering
News
Stoke Therapeutics Announces Proposed Public Offering
Rhea-AI Summary
Stoke Therapeutics, Inc. (STOK) announces a proposed underwritten public offering to raise up to $75 million through the sale of common stock. The company plans to use the proceeds for research, clinical development, manufacturing of product candidates, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
37.71%
Tags
offering
-
News
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Stoke Therapeutics, Inc. reported financial results for the full year ended December 31, 2023, with $201.4 million in cash, cash equivalents, and marketable securities expected to fund operations until 2025. Revenue for 2023 was $8.8 million, net loss was $104.7 million, research and development expenses were $82.2 million, and general and administrative expenses were $41.3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
58.31%
Tags
earnings
-
News
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
Rhea-AI Summary
Stoke Therapeutics (STOK) announces positive data from Phase 1/2a studies of STK-001 for Dravet syndrome treatment, showing substantial reductions in convulsive seizure frequency and cognitive improvements. The company plans to discuss registrational study design with regulatory agencies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
58.31%
Tags
none
News
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Rhea-AI Summary
Stoke Therapeutics, Inc. (Nasdaq: STOK) has granted stock options to 2 new employees, totaling 13,300 shares of common stock, with an exercise price of $4.99 per share. Each option will vest over a 4-year period, with 1/4th of the shares vesting on the one-year anniversary and the remaining shares vesting monthly over the following 36 months, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
none
-
News
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024
Rhea-AI Summary
Stoke Therapeutics, Inc. (STOK) announces strategic priorities and anticipated milestones for 2024, including data anticipated in Q1 2024 from studies of STK-001 for the treatment of Dravet syndrome, end of Phase 1/2a study results, OLE data from patients receiving ongoing treatment, and pending Phase 3 planning meetings with regulators. As of September 30, 2023, the company had $214.7 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to the end of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
none
-
News
Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Stoke Therapeutics, Inc. (Nasdaq: STOK) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The company focuses on upregulating protein expression with RNA-based medicines to address severe diseases. A live audio webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News
Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting
Rhea-AI Summary
Stoke Therapeutics, Inc. (Nasdaq: STOK) presented clinical data at the American Epilepsy Society (AES) 2023 Annual Meeting, highlighting STK-001's potential to address Dravet syndrome. The 2-year natural history study showed no meaningful improvement in convulsive seizures despite treatment with anti-seizure medicines. However, STK-001 clinical studies demonstrated substantial and sustained reductions in seizure frequency and improvements in cognition and behavior, supporting the potential for disease modification.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.22%
Tags
none
Stock STOK logo
Stoke Therapeutics Inc

Nasdaq:STOK

STOK Rankings

#2802 Ranked by Market Cap
#5271 Ranked by Stock Gains
N/A Ranked by Dividends

STOK Stock Data

662.24M
35.46M
4.64%
88.08%
10.69%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Bedford

About STOK

stoke is developing antisense oligonucleotide medicines that target rna splicing to increase gene expression for the treatment of severe genetic diseases.